Investment analysts at Royal Bank Of Canada assumed coverage on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a report issued on Thursday. The firm set a “sector perform” rating on the biopharmaceutical company’s stock.
Other research analysts also recently issued reports about the stock. Piper Jaffray Companies boosted their price objective on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a research report on Tuesday, June 20th. BMO Capital Markets set a $491.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $472.00 price objective (up from $469.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Jefferies Group LLC reissued a “hold” rating and set a $471.00 price objective (up from $418.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Finally, Leerink Swann reissued an “outperform” rating and set a $580.00 price objective (up from $573.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $496.35.
Regeneron Pharmaceuticals (NASDAQ REGN) traded up 0.81% during midday trading on Thursday, hitting $441.30. 873,444 shares of the stock traded hands. Regeneron Pharmaceuticals has a 52 week low of $325.35 and a 52 week high of $543.55. The company has a market capitalization of $46.79 billion, a price-to-earnings ratio of 44.27 and a beta of 1.65. The stock’s 50-day moving average price is $479.23 and its 200 day moving average price is $445.02.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The company’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.82 EPS. On average, equities research analysts predict that Regeneron Pharmaceuticals will post $14.90 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.chaffeybreeze.com/2017/09/14/regeneron-pharmaceuticals-inc-regn-research-coverage-started-at-royal-bank-of-canada.html.
In other news, SVP Robert E. Landry sold 427 shares of the stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $493.43, for a total value of $210,694.61. Following the transaction, the senior vice president now owns 9,099 shares in the company, valued at approximately $4,489,719.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert E. Landry sold 189 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. Insiders sold a total of 120,690 shares of company stock worth $57,732,183 in the last quarter. Company insiders own 10.40% of the company’s stock.
Several large investors have recently modified their holdings of the company. Intl Fcstone Inc. purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $346,000. Lord Abbett & CO. LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $51,931,000. Toronto Dominion Bank increased its holdings in Regeneron Pharmaceuticals by 25.8% in the 2nd quarter. Toronto Dominion Bank now owns 25,835 shares of the biopharmaceutical company’s stock worth $12,686,000 after acquiring an additional 5,295 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $713,000. Finally, Public Employees Retirement System of Ohio increased its holdings in Regeneron Pharmaceuticals by 1.6% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 54,288 shares of the biopharmaceutical company’s stock worth $26,663,000 after acquiring an additional 867 shares in the last quarter. Hedge funds and other institutional investors own 67.96% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.